Pfizer and BioNTech could secure emergency US and European authorisation for their Covid-19 vaccine next month, the drugmaker has said. Final trial results showed that the vaccine had a 95% success rate and no serious side effects. The US Food and Drug Administration could grant emergency-use by the middle of December, BioNTech chief executive Ugur Sahin told Reuters TV. Conditional approval in the European Union could be secured in the second half of December, he added. If all goes well, the drugmaker is likely to start delivering vaccine before Christmas.